Contineum appoints Diego Miralles, M.D. to board of directors

Contineum Therapeutics, Inc.

Dr. Miralles appointed as Class II director effective March 14, 2025, term expiring at 2026 annual meeting.
He previously served as an advisor under an agreement with monthly retainer of up to $16,000 and an option for 5,000 shares at $17.92.
As a non-employee director, he will receive standard cash and equity compensation including an initial option grant for 29,500 shares.
Dr. Miralles is not considered independent under Nasdaq listing standards.
He currently serves as CEO of AZURNA Therapeutics and serves on the board of Artiva Biotherapeutics.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Diego Miralles, M.D.

Director

CTNM · Contineum Therapeutics, Inc.

Effective: 2025-03-14
Filed: March 17, 2025, 7:59 PM ET

On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Diego Miralles, M.D. was appointed as Director at Contineum Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025.

View on SEC.gov

Contineum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-007998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.